Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Medicare’s high cost end stage renal disease patients

Merrill Goozner
Conditions
June 11, 2011
Share
Tweet
Share

Anyone who thinks America has the best health care system in the world ought to take a look at its miserable record on caring for end stage renal disease patients on dialysis.

About one of every five people who go on dialysis dies in the first year here, compared to less than one in seven in Europe and one in sixteen in Japan. Even after adjusting for age, gender, race and 25 co-morbid conditions (the primary causes of kidney failure are poorly treated diabetes and hypertension), the U.S. mortality rate is one-third higher than Europe and nearly four times the Japanese rate, according to a recent analysis. The average life expectancy of Americans on dialysis is about three years.

Taxpayers pay exorbitant sums for these poor outcomes. The Centers for Medicare and Medicaid Services, which cover treatment for end-stage renal disease, even for the non-elderly, spent $24 billion on dialysis in 2007. Just one percent of Medicare beneficiaries who are on dialysis generated a whopping 5.6 percent of the agency’s bills. Moreover, the obesity epidemic guarantees that those numbers will only shoot up in the years ahead since more than 100,000 people are now entering dialysis ever year – more than the number that die from the one of the conditions that leads to kidney failure.

You would think that the nephrology community would be up in arms over these alarming statistics, or at least looking for a less expensive and hopefully more effective way of caring for these predominantly poor patients. Yet two new studies in the Archives of Internal Medicine reveal just the opposite. A small and declining number of patients receive peritoneal dialysis, an at-home alternative that generates comparable outcomes with greater patient satisfaction at 19 percent lower cost – $53,446 per year for patients on peritoneal dialysis versus $73,008 on in-clinic hemodialysis in 2007, according to one study.

And the other study showed nephrologists do a poor job of informing patients about this three-decade-old alternative. Peritoneal dialysis (PD) has declined from 14.4 percent of the dialysis population in 1995 to 7.1 percent in 2007. In an accompanying editorial, Dr. Kirsten Johansen, a nephrologist at the University of California at San Francisco, wrote:

The data available so far have led experts to conclude that low PD utilization is, at least in part, the fault of nephrologists, who are not discussing PD options with patients, possibly owing to concern about higher mortality (which the latest study shows is incorrect), inadequate training of nephrologists, nephrologists’ bias against PD, pressures to fill HD (hemodialysis) chairs, late referral to nephrologists, and other reasons.

I was intrigued by the “pressures to fill HD chairs” statement in the editorial, so I sent Dr. Johansen an email late last night. Were there any financial incentives that encouraged nephrologists associated with the for-profit dialysis clinics that discouraged use of this less costly alternative?

“Typically the dialysis clinic owners will hire a nephrologist to be medical director,” she wrote back. “This reimbursement isn’t tied to bringing in patients but the nephrologist then has an interest in the success of the clinic, and since they have to see their patients in that unit once a week to receive maximum Medicare reimbursement, it’s better to have several patients there on each shift to increase efficiency. I don’t think there is any solid data to say that this has an impact on how well nephrologists inform patients, but many have speculated about this.”

Last year, CMS added a new benefit for end-stage renal disease patients. The agency will reimburse physicians for up to six counseling sessions just before their patients are about to go on dialysis. The agency wants more people to consider the PD alternative, which involves removal and re-infusion of an abdominal cavity fluid about four times a day and can be self-administered at home. That doesn’t sound like fun, but patients consistently rank it as a  better experience than having to go to a distant clinic three times a week for four- to six-hour sessions where they are hooked up to a machine.

If half the new dialysis patients in the U.S. chose PD over HD, Medicare could save more than $5 billion a year. The additional counseling needed to get to those rates might even jump-start the long overdue conversation about why so many people do so poorly once they’re on dialysis; why so many have failing kidneys in the first place; and what preventive measures can be taken to deal with this burgeoning public health fiasco.

Merrill Goozner is a freelance writer, independent researcher and consultant who blogs at Gooznews on Health.

Submit a guest post and be heard on social media’s leading physician voice.

Prev

Securing mobile devices in healthcare

June 11, 2011 Kevin 2
…
Next

MKSAP: 50-year-old woman with advanced multiple myeloma

June 11, 2011 Kevin 3
…

ADVERTISEMENT

Tagged as: Medicare, Patients, Specialist

Post navigation

< Previous Post
Securing mobile devices in healthcare
Next Post >
MKSAP: 50-year-old woman with advanced multiple myeloma

ADVERTISEMENT

More by Merrill Goozner

  • a desk with keyboard and ipad with the kevinmd logo

    Curbing Medicare costs: Are seniors or the government responsible?

    Merrill Goozner
  • a desk with keyboard and ipad with the kevinmd logo

    Will health reform survive the Supreme Court?

    Merrill Goozner
  • a desk with keyboard and ipad with the kevinmd logo

    A look behind the growing cost of cancer drugs

    Merrill Goozner

More in Conditions

  • A poem on kidney cancer survivorship and the annual scan

    Michele Luckenbaugh
  • Hashimoto’s disease in adolescent girls: Why it’s often overlooked

    Callia Georgoulis
  • Why doctors ignore their own advice on hydration and health

    Amanda Shim, MD
  • Low testosterone in men: a doctor’s guide to TRT safety

    Martina Ambardjieva, MD, PhD
  • Uterine aging in IVF: Why the “soil” matters as much as the seed

    Oluyemisi Famuyiwa, MD
  • How modern health care design strains patients and clinicians

    Deanna J. Gilmore, RDH
  • Most Popular

  • Past Week

    • Alex Pretti: a physician’s open letter defending his legacy

      Mousson Berrouet, DO | Physician
    • The elephant in the room: Why physician burnout is a relationship problem

      Tomi Mitchell, MD | Physician
    • ADHD and cannabis use: Navigating the diagnostic challenge

      Farid Sabet-Sharghi, MD | Conditions
    • Leading with love: a physician’s guide to clarity and compassion

      Jessie Mahoney, MD | Physician
    • Urological analysis of delayed cancer diagnoses in political figures [PODCAST]

      The Podcast by KevinMD | Podcast
    • Racial disparities in pancreatic cancer screening cost Black lives [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Why patient trust in physicians is declining

      Mansi Kotwal, MD, MPH | Physician
    • Physician on-call compensation: the unpaid labor driving burnout

      Corinne Sundar Rao, MD | Physician
    • How environmental justice and health disparities connect to climate change

      Kaitlynn Esemaya, Alexis Thompson, Annique McLune, and Anamaria Ancheta | Policy
    • Will AI replace primary care physicians?

      P. Dileep Kumar, MD, MBA | Tech
    • A physician father on the Dobbs decision and reproductive rights

      Travis Walker, MD, MPH | Physician
    • Is tramadol really ineffective and risky?

      John A. Bumpus, PhD | Meds
  • Recent Posts

    • Racial disparities in pancreatic cancer screening cost Black lives [PODCAST]

      The Podcast by KevinMD | Podcast
    • A poem on kidney cancer survivorship and the annual scan

      Michele Luckenbaugh | Conditions
    • AI-enabled clinical data abstraction: a nurse’s perspective

      Pamela Ashenfelter, RN | Tech
    • Why clinical excellence isn’t enough to sustain a physician-owned hospital

      Dr. Bhavin P. Vadodariya | Physician
    • Emergency department metrics vs. reality: Why the numbers lie

      Marilyn McCullum, RN | Policy
    • Hashimoto’s disease in adolescent girls: Why it’s often overlooked

      Callia Georgoulis | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Alex Pretti: a physician’s open letter defending his legacy

      Mousson Berrouet, DO | Physician
    • The elephant in the room: Why physician burnout is a relationship problem

      Tomi Mitchell, MD | Physician
    • ADHD and cannabis use: Navigating the diagnostic challenge

      Farid Sabet-Sharghi, MD | Conditions
    • Leading with love: a physician’s guide to clarity and compassion

      Jessie Mahoney, MD | Physician
    • Urological analysis of delayed cancer diagnoses in political figures [PODCAST]

      The Podcast by KevinMD | Podcast
    • Racial disparities in pancreatic cancer screening cost Black lives [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Why patient trust in physicians is declining

      Mansi Kotwal, MD, MPH | Physician
    • Physician on-call compensation: the unpaid labor driving burnout

      Corinne Sundar Rao, MD | Physician
    • How environmental justice and health disparities connect to climate change

      Kaitlynn Esemaya, Alexis Thompson, Annique McLune, and Anamaria Ancheta | Policy
    • Will AI replace primary care physicians?

      P. Dileep Kumar, MD, MBA | Tech
    • A physician father on the Dobbs decision and reproductive rights

      Travis Walker, MD, MPH | Physician
    • Is tramadol really ineffective and risky?

      John A. Bumpus, PhD | Meds
  • Recent Posts

    • Racial disparities in pancreatic cancer screening cost Black lives [PODCAST]

      The Podcast by KevinMD | Podcast
    • A poem on kidney cancer survivorship and the annual scan

      Michele Luckenbaugh | Conditions
    • AI-enabled clinical data abstraction: a nurse’s perspective

      Pamela Ashenfelter, RN | Tech
    • Why clinical excellence isn’t enough to sustain a physician-owned hospital

      Dr. Bhavin P. Vadodariya | Physician
    • Emergency department metrics vs. reality: Why the numbers lie

      Marilyn McCullum, RN | Policy
    • Hashimoto’s disease in adolescent girls: Why it’s often overlooked

      Callia Georgoulis | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Medicare’s high cost end stage renal disease patients
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...